

## **A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York**

Medini K. Annavajhala<sup>1\*</sup>, Hiroshi Mohri<sup>2\*</sup>, Pengfei Wang<sup>2</sup>, Jason E. Zucker<sup>1</sup>, Zizhang Sheng<sup>2</sup>, Angela Gomez-Simmonds<sup>1</sup>, Trevor Bedford<sup>3</sup>, David D. Ho<sup>1,2,4#</sup>, Anne-Catrin Uhlemann<sup>1#</sup>

<sup>1</sup> Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

<sup>2</sup> Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

<sup>3</sup> Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>4</sup> Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.

\* Medini K. Annavajhala and Hiroshi Mohri contributed equally to this work.

# David D. Ho and Anne-Catrin Uhlemann contributed equally to this work.

Address correspondence to [au2110@cumc.columbia.edu](mailto:au2110@cumc.columbia.edu) or [dh2994@cumc.columbia.edu](mailto:dh2994@cumc.columbia.edu).

1 **Summary**

2 **Recent months have seen surges of SARS-CoV-2 infection across the globe along with**  
3 **considerable viral evolution<sup>1-3</sup>. Extensive mutations in the spike protein may threaten**  
4 **efficacy of vaccines and therapeutic monoclonal antibodies<sup>4</sup>. Two signature mutations of**  
5 **concern are E484K, which plays a crucial role in the loss of neutralizing activity of**  
6 **antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here,**  
7 **we report the emergence of a novel variant lineage B.1.526 that contains E484K and its**  
8 **alarming rise to dominance in New York City in recent months. This variant is partially or**  
9 **completely resistant to two therapeutic monoclonal antibodies in clinical use. It is also less**  
10 **susceptible to neutralization by convalescent plasma or vaccinee sera by 4.1-fold or 3.3-3.6-**  
11 **fold, respectively. The B.1.526 lineage has now been reported from at least 32 states in the**  
12 **US and numerous other countries. B.1526 has been outpacing B.1.1.7 in Northern**  
13 **Manhattan, and both variants have been spreading throughout New York with comparable**  
14 **estimated doubling times. Such transmission dynamics, together with its resistance to**  
15 **therapeutic antibodies, would warrant B.1.526 as a SARS-CoV-2 variant of concern.**

16

17

## 18 **Main**

19 While evolution of SARS-CoV-2 was deemed to be slow at the beginning of the global pandemic<sup>5</sup>,  
20 at least four major variants of concern have emerged over the past four months<sup>1-3</sup>. These lineages  
21 are each characterized by numerous mutations in the spike protein, raising concerns that they may  
22 escape from therapeutic monoclonals and vaccine-induced antibodies. The hallmark mutation of  
23 B.1.1.7, the first described SARS-CoV-2 variant of concern that emerged in the UK, is N501Y  
24 located in the receptor-binding domain (RBD) of spike<sup>1</sup>. This variant is seemingly more  
25 transmissible and virulent<sup>6-8</sup>, perhaps due to a higher binding affinity of N501Y for ACE2<sup>9</sup>. Two  
26 other variants of concern, B.1.351 (first detected in South Africa)<sup>2</sup> and P.1 (first described in  
27 Brazilian travelers)<sup>3</sup>, share the N501Y mutation with B.1.1.7 but contain an E484K substitution in  
28 RBD<sup>2,3</sup>. Epidemiological evidence suggests that P.1 emerged as part of a second surge in Manaus,  
29 Brazil despite a high pre-existing seroprevalence of SARS-CoV-2 in the population. Reinfections  
30 with P.1, as well as with another related Brazilian variant P.2 that also harbors E484K, have been  
31 documented<sup>10,11</sup>.

32  
33 Our previous study on B.1.351 demonstrated that this variant is refractory to neutralization by a  
34 number of monoclonal antibodies directed to the top of RBD, including several that have received  
35 emergency use authorization<sup>4</sup>. Moreover, this variant was markedly more resistant to  
36 neutralization by convalescent plasma and vaccinee sera. Importantly, these effects were in part  
37 mediated by the E484K mutation. These findings are worrisome in light of recent reports that three  
38 vaccine trials showed a substantial drop in efficacy in South Africa<sup>12-14</sup>. To systematically screen  
39 our patient population in Northern Manhattan for B.1.351 and other E484K variants such as P.1  
40 and P.2, as well as B.1.1.7, we implemented a rapid PCR-based screen for signature mutations  
41 combined with genomic surveillance.

42

## 43 **Rapid screening for signature SARS-CoV-2 mutations**

44 We first developed rapid PCR-based single-nucleotide-polymorphism assays to search for N501Y  
45 and E484K mutations (see schematic in Extended Data Fig. 1) in clinical samples known to be  
46 positive for SARS-CoV-2 and stored in the Columbia University Biobank, a biorepository of  
47 SARS-CoV-2 patient specimens from hospitals and outpatient clinics within our medical system.  
48 Patient and clinical testing information was extracted from the COVID-Care database<sup>15</sup>. Between

49 November 1, 2020 and March 5, 2021, a total of 38,987 nasopharyngeal swabs underwent clinical  
50 testing for SARS-CoV-2 at our medical center, with 3,350 positive samples identified; 2,353  
51 positive samples were available through the Columbia University Biobank for our study. We  
52 screened 1,751 samples from this time-period (74.5% of all stored samples) for the two signature  
53 mutations. We identified 176 samples with E484K (13.0% of samples that showed a signal in our  
54 genotyping assay) and 41 (3.4%) with N501Y. Only one sample contained both mutations. The  
55 earliest case with E484K was collected in mid-November 2020. Subsequently, there was a  
56 substantial increase in E484K-positive cases over time (Fig. 1a), from 2.5% in early November to  
57 8.9% by mid-January, and ultimately to 24.3% between February 21<sup>st</sup> and March 5<sup>th</sup>, 2021. Viruses  
58 harboring N501Y also increased over time, albeit more gradually, from the earliest detection in  
59 mid-January to 5.3% of screened isolates by the beginning of March.

60

### 61 **Genomics of variant and wildtype SARS-CoV-2**

62 We performed whole genome nanopore sequencing on samples flagged as potential N501Y- or  
63 E484K-harboring strains with Ct values below 35 (n=132). We also sequenced samples negative  
64 for these signature mutations obtained during the same time period, all with Ct values below 35  
65 (n=150). Sequencing results verified the E484K and N501Y substitutions in all samples identified  
66 by our screening PCR assays. Based on genomic sequencing, we performed phylogenetic analyses  
67 on all variant and non-variant genomes from our collection (Fig. 1b) and including publicly  
68 available genomic data (Extended Data Fig. 2). Amongst cases with N501Y, 17 (81.0% of 21  
69 sequenced N501Y isolates) were identified as belonging to the B.1.1.7 lineage. One case with  
70 E484K was identified as P.2 and two as the parent lineage for the P.1 and P.2 strains, B.1.1.28.  
71 One sample which harbored both N501Y and E484K based on our screening assay was identified  
72 as B.1.351. However, quite unexpectedly, the large majority of the remaining cases with E484K  
73 (n=98/110, 89.1%) fell within a single lineage, B.1.526<sup>16</sup>. Further phylogenetic examination  
74 showed that the B.1.526 lineage is comprised of two sub-lineages harboring either E484K  
75 (B.1.526-E484K) or S477N (B.1.526-S477N) (Fig. 1c). From sequenced samples, which were  
76 negative for E484K and N501Y based on our PCR screen, we also noted the presence of B.1.526-  
77 S477N (n=26) in our collection. Strains that did not harbor E484K, N501Y, or S477N belonged to  
78 29 distinct lineages; the most common were B.1.2 (n=28, 18.7%), B.1 (n=25, 16.7%), B.1.1.304  
79 (n=12, 8.0%), and B.1.243 (n=11, 7.3%) among 150 sequences collected concurrently.

80

### 81 **Signature mutations of the B.1.526 lineage**

82 We first identified signature spike-protein mutations in the B.1.526 lineage by comparing all  
83 genomes generated as a part of this study. In Figure 1c, all unique patterns of S-gene mutations in  
84 our collection are displayed. Both B.1.526-E484K and B.1.526-S477N share characteristic spike-  
85 protein mutations L5F, T95I, D253G, D614G, and either A701V or Q957R along with either  
86 E484K or S477N. Non-spike mutations widely shared by B.1.526 isolates include: T85I in ORF1a-  
87 nsp2; L438P in ORF1a-nsp4, a 9bp deletion  $\Delta$ 106-108 in ORF1a-nsp6; P323L in ORF1b-nsp12;  
88 Q88H in ORF1b-nsp13; Q57H in ORF3a; and P199L and M234I in the N gene.

89

90 To further investigate the evolution of B.1.526, we performed phylogenetic analyses on genomes  
91 in this collection and in GISAID harboring the 9bp deletion  $\Delta$ 106-108 in ORF1a-nsp6, along with  
92 mutation A20262G that uniquely defines the parent clade containing B.1.526 and related viruses  
93 (Fig. 2a). We observed a stepwise emergence of these key mutations, with T95I, D253G, and L5F  
94 appearing in the earliest phylogenetic nodes. Isolates subsequently branched into three sub-  
95 lineages, with two major groups B.1.526-E484K and B.1.526-S477N containing A701V and one  
96 smaller sub-lineage B.1.526-S477N containing Q957R.

97

98 Figure 2b displays the localization of B.1.526 signature spike mutations within the S protein  
99 structure. D253G resides in the antigenic supersite within the N-terminal domain<sup>17</sup>, which is a  
100 target for neutralizing antibodies<sup>18</sup>, whereas the E484K is situated at the RBD interface with the  
101 cellular receptor ACE2. The A701V mutation near the furin cleavage site is also shared with  
102 variant B.1.351.

103

### 104 **Antibody neutralization of B.1.526**

105 The impact of the signature S protein mutations in B.1.526 on antibody neutralization was assessed  
106 using vesicular stomatitis virus (VSV) based pseudoviruses as previously described<sup>4,18</sup>.  
107 Pseudoviruses containing S477N or E484K alone and all five signature mutations (L5F, T95I,  
108 D253G, A701V, and E484K or S477N), termed NY $\Delta$ 5(E484K) or NY $\Delta$ 5(S477N), were  
109 constructed and subjected to neutralization by 12 monoclonal antibodies including 4 with  
110 emergency use authorization, 20 convalescent plasma, and 22 vaccinee sera. The specifics of these

111 monoclonal antibodies and clinical specimens were previously reported<sup>4</sup>. As shown in Figure 3a,  
112 the neutralizing activity of 12 monoclonal antibodies covering all epitopes on RBD was essentially  
113 unaltered against the S477N and NYΔ5(S477N) pseudoviruses, showing that this mutation has no  
114 discernible antigenic impact. However, against E484K and NYΔ5 pseudoviruses, the activities of  
115 several antibodies were either impaired or lost, including REGN10933 and LY-CoV555 that are  
116 already in clinical use. Likewise, neutralizing activities of convalescent plasma or vaccinee sera  
117 were lowered by 4.1-fold or 3.3-3.6-fold, respectively, against NYΔ5(E484K) (Fig. 3b), thereby  
118 raising the specter that risks of re-infection or vaccine breakthrough due to B.1.526-E484K may  
119 be heightened. A comparative analysis with other variants of concern (Fig. 3c) showed that such  
120 risks are likely lower than B.1.351 but higher than P.1 and B.1.1.7. Overall, these results  
121 demonstrate the need to modify our antibody therapy and to monitor the efficacy of current  
122 vaccines in regions where B.1.526-E484K is prevalent.

123

#### 124 **Clinical comparisons of patients infected with E484K versus wildtype virus**

125 Patients with E484K variant viruses were comparable in gender, age, race and ethnicity to those  
126 with wildtype SARS-CoV-2 (Extended Data Table 1). There were no significant differences in the  
127 rates of major comorbidities across E484K-positive and -negative groups, although patients  
128 harboring E484K isolates trended toward a higher rate of diabetes mellitus (30.8 vs 23.6%,  
129  $p=0.07$ ). The highest level of care required and maximal oxygen requirement were comparable  
130 between groups, although more patients with E484K isolates were still hospitalized at the time of  
131 this study (6.7 vs 2.8%,  $p=0.02$ ). Notably, the cycle threshold (Ct) values for E484K isolates were  
132 significantly lower than wildtype isolates (mean 30.4 vs 31.8,  $p=0.01$ ), indicating a modestly  
133 higher viral load in these variant samples.

134

#### 135 **Surge in B.1.526 across NYC and the U.S.**

136 In recent weeks, we have observed a notable increase in isolates harboring not only B.1.526 with  
137 E484K, but also the separate sub-lineage with S477N (Fig. 1b). Prevalence of this novel variant  
138 B.1.526 has surged alarmingly in our hospital catchment area over the past few months, at a rate  
139 significantly outpacing that of B.1.1.7, with an estimated doubling time of 15 days (Fig. 4a).  
140 However, looking more broadly at publicly available data through March 21, we see similar  
141 logistic growth rates of B.1.1.7 and B.1.526 in viruses collected from New York State, with growth

142 rate of B.1.526 estimated at 0.032 per day (95% CI 0.029–0.036) and growth rate of B.1.1.7  
143 estimated at 0.040 per day (95% CI 0.037–0.043) (Fig. 4b). These differences may reflect distinct  
144 sampling and sequencing strategies. The data in Figure 4a represent unbiased comprehensive  
145 screening at a single site, which has consistently shown higher prevalence of B.1.526-E484K. In  
146 contrast, results in Figure 4b represent a larger geographic area and relies on public data subject to  
147 reporting biases. This may include preferential sequencing of samples with S-gene drop out in a  
148 diagnostic PCR<sup>8</sup>. At a minimum, B.1.526 is rising at a rate on par with B.1.1.7, a variant known  
149 to be substantially more transmissible<sup>19</sup>.

150  
151 Patients with E484K variants were at first geographically concentrated in two distinct  
152 neighborhoods in the catchment area of our hospital system (Fig. 4c, top panel). However,  
153 especially by March 2021, many others were found scattered throughout the New York area  
154 without evidence for a single outbreak (Fig. 4c, middle and bottom panels). Indeed, based on data  
155 extracted from patient medical records, patients with SARS-CoV-2 harboring E484K were also  
156 more likely to reside inside rather than outside the greater metropolitan area, compared to those  
157 with non-variant strains ( $p=0.03$ , Extended Data Table 1).

158  
159 Using patient location data for B.1.526 genomes generated as part of this study ( $n=132$ ) as well as  
160 for sequences from GISAID ( $n=2,106$ ) (see Supplementary Table 2)<sup>16</sup>, we found that B.1.526  
161 genomes, primarily harboring E484K, were initially predominantly from samples collected in the  
162 Northeastern US (Fig. 4d, top panel). Even by March 2021 (Fig. 4d, middle and bottom panels),  
163 B.1.526 is concentrated in New York and surrounding states. This suggests that B.1.526, and  
164 B.1.526-E484K in particular, is now widespread in the region, the original epicenter of COVID-  
165 19 in the US<sup>20,21</sup>. Of increasing concern, however, is the spread of B.1.526 over the past two  
166 months to over 32 states across the country as well as internationally (Fig. 4d, middle and bottom  
167 panels).

168  
169 **Discussion**  
170 Here we report the emergence of E484K in a novel lineage, B.1.526, and its alarming surge in New  
171 York City. Neutralization assays using pseudoviruses containing mutations of the S protein in  
172 B.1.526 demonstrate that the activities of several antibodies were either impaired or lost, including

173 two (Ly-CoV555 and REGN10933) already in clinical use (Fig. 3a). Furthermore, neutralizing  
174 activities of convalescent plasma or vaccinee sera were lower against B.1.526 harboring E484K  
175 (Fig. 3b). Going forward, it will be important to monitor the antigenic impact of this variant on re-  
176 infection or vaccine breakthrough. The S477N mutation, a key signature of another B.1.526 sub-  
177 lineage, did not have an impact on neutralizing monoclonal antibodies directed to the RBD (Fig.  
178 3a). These findings underscore the importance of the E484K mutation, which has emerged in at  
179 least 108 different lineages of SARS-CoV-2<sup>22</sup>, a real testament to convergent evolution. This raises  
180 the possibility that E484K can rapidly emerge in multiple clonal backgrounds and may warrant  
181 targeted screening for this key mutation in addition to robust genomic surveillance programs. The  
182 greatest threat of B.1.526 appears to be its ease of spread. It is keeping pace with B.1.1.7 in New  
183 York State (Fig. 4b) and surpassing it in the catchment area of our medical center (Fig. 4a). This  
184 apparent increased transmissibility is of great concern. Overall, the identification of B.1.526  
185 reported here serves to highlight the need for concerted local, national, and international  
186 surveillance programs to track and contain the spread of novel SARS-CoV-2 variants.




187 **References**


- 188 1 Rambaut, A. *et al.* Preliminary genomic characterisation of an emergent SARSCoV-2  
189 lineage in the UK defined by a novel set of spike mutations. ,  
190 <[https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-  
191 sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)>  
192 (2020).
- 193 2 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory  
194 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations  
195 in South Africa. *medRxiv*, 2020.2012.2021.20248640,  
196 doi:10.1101/2020.12.21.20248640 (2020).
- 197 3 Faria, N. R. *et al.* Genomic characterisation of an emergent SARS-CoV-2 lineage in  
198 Manaus: preliminary findings. (2021).
- 199 4 Wang, P. *et al.* Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.  
200 *Nature*, doi:10.1038/s41586-021-03398-2 (2021).
- 201 5 Duchene, S. *et al.* Temporal signal and the phylodynamic threshold of SARS-CoV-2.  
202 *Virus Evol* **6**, veaa061, doi:10.1093/ve/veaa061 (2020).
- 203 6 Iacobucci, G. Covid-19: New UK variant may be linked to increased death rate, early  
204 data indicate. *BMJ* **372**, n230, doi:10.1136/bmj.n230 (2021).
- 205 7 Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from  
206 linking epidemiological and genetic data. *medRxiv*, 2020.2012.2030.20249034,  
207 doi:10.1101/2020.12.30.20249034 (2021).
- 208 8 Washington, N. L. *et al.* Genomic epidemiology identifies emergence and rapid  
209 transmission of SARS-CoV-2 B.1.1.7 in the United States. *medRxiv*,  
210 doi:10.1101/2021.02.06.21251159 (2021).
- 211 9 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-  
212 binding domain that affect recognition by polyclonal human plasma antibodies. *Cell*  
213 *Host Microbe* **29**, 463-476 e466, doi:10.1016/j.chom.2021.02.003 (2021).
- 214 10 Zucman, N., Uhel, F., Descamps, D., Roux, D. & Ricard, J. D. Severe reinfection with  
215 South African SARS-CoV-2 variant 501Y.V2: A case report. *Clin Infect Dis*,  
216 doi:10.1093/cid/ciab129 (2021).
- 217 11 Nonaka, C. K. V. *et al.* Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K  
218 Spike Mutation, Brazil. *Emerg Infect Dis* **27**, doi:10.3201/eid2705.210191 (2021).
- 219 12 Wadman, M. & Cohen, J. *Novavax vaccine delivers 89% efficacy against COVID-19 in*  
220 *U.K.—but is less potent in South Africa*,  
221 <[https://www.sciencemag.org/news/2021/01/novavax-vaccine-delivers-89-  
223 efficacy348against-covid-19-uk-less-potent-south-africa](https://www.sciencemag.org/news/2021/01/novavax-vaccine-delivers-89-<br/>222 efficacy348against-covid-19-uk-less-potent-south-africa)> (2021).
- 223 13 Callaway, E. & Mallapaty, S. Novavax offers first evidence that COVID vaccines protect  
224 people against variants. *Nature* **590**, 17, doi:10.1038/d41586-021-00268-9 (2021).
- 225 14 Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the  
226 B.1.351 Variant. *N Engl J Med*, doi:10.1056/NEJMoa2102214 (2021).
- 227 15 Miller, E. H. *et al.* Pretest Symptom Duration and Cycle Threshold Values for Severe  
228 Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain  
229 Reaction Predict Coronavirus Disease 2019 Mortality. *Open Forum Infectious Diseases*  
230 **8**, doi:10.1093/ofid/ofab003 (2021).

- 231 16 West, A. P., Barnes, C. O., Yang, Z. & Bjorkman, P. J. SARS-CoV-2 lineage B.1.526  
232 emerging in the New York region detected by software utility created to query the  
233 spike mutational landscape. *bioRxiv*, 2021.2002.2014.431043,  
234 doi:10.1101/2021.02.14.431043 (2021).
- 235 17 Cerutti, G. *et al.* Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-  
236 Terminal Domain Target a Single Supersite. *bioRxiv*, 2021.2001.2010.426120,  
237 doi:10.1101/2021.01.10.426120 (2021).
- 238 18 Liu, L. *et al.* Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2  
239 spike. *Nature* **584**, 450-456, doi:10.1038/s41586-020-2571-7 (2020).
- 240 19 Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage  
241 B.1.1.7 in England. *Science*, doi:10.1126/science.abg3055 (2021).
- 242 20 Health, N. Y. C. D. o. *COVID-19: Data*, <<https://www1.nyc.gov/site/doh/covid/covid-19-data-trends.page#antibody>> (2021).
- 244 21 Lasek-Nesselquist, E., Lapierre, P., Schneider, E., George, K. S. & Pata, J. The localized  
245 rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York  
246 State. *medRxiv*, 2021.2002.2026.21251868, doi:10.1101/2021.02.26.21251868  
247 (2021).
- 248 22 Alaa Abdel Latif, K. G., Julia L. Mullen, Emily Haag, Ginger Tsueng, Nate Matteson, Mark  
249 Zeller, Chunlei Wu, Kristian G. Andersen, Andrew I. Su, Laura D. Hughes, and the  
250 Center for Viral Systems. *B.1.526 Lineage Report*, <<https://outbreak.info/situation-reports/S-E484K>> (2021).
- 252 23 Wang, P. *et al.* Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody  
253 Neutralization. *bioRxiv*, doi:10.1101/2021.03.01.433466 (2021).
- 254 24 Smyrlaki, I. *et al.* Massive and rapid COVID-19 testing is feasible by extraction-free  
255 SARS-CoV-2 RT-PCR. *Nat Commun* **11**, 4812, doi:10.1038/s41467-020-18611-5  
256 (2020).
- 257 25 Quick, J. *Artic Protocol*, <<https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>> (2021).
- 259 26 Demaio, N. *Masking strategies for SARS-CoV-2*, <<https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480>> (2020).
- 261 27 Hadfield, J. *et al.* Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*  
262 **34**, 4121-4123, doi:10.1093/bioinformatics/bty407 (2018).
- 263 28 Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic  
264 Inference in the Genomic Era. *Mol Biol Evol* **37**, 1530-1534,  
265 doi:10.1093/molbev/msaa015 (2020).
- 266 29 Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic  
267 analysis. *Virus Evol* **4**, vex042, doi:10.1093/ve/vex042 (2018).
- 268 30 Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from  
269 vision to reality. *Euro Surveill* **22**, doi:10.2807/1560-7917.ES.2017.22.13.30494  
270 (2017).
- 271 31 Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV  
272 antibody. *Nature* **583**, 290-295, doi:10.1038/s41586-020-2349-y (2020).
- 273 32 Zost, S. J. *et al.* Rapid isolation and profiling of a diverse panel of human monoclonal  
274 antibodies targeting the SARS-CoV-2 spike protein. *Nat Med* **26**, 1422-1427,  
275 doi:10.1038/s41591-020-0998-x (2020).




276 33 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent  
277 individuals. *Nature* **584**, 437-442, doi:10.1038/s41586-020-2456-9 (2020).  
278 34 Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist  
279 genomic epidemiology. *Nat Microbiol* **5**, 1403-1407, doi:10.1038/s41564-020-0770-  
280 5 (2020).  
281  
282



284 **Figure 1. Prevalence of E484K-harboring SARS-CoV-2 and B.1.526.** (a) Detection of viruses  
285 with key signature mutations in spike over time. The earliest detected E484K-harboring variant  
286 was collected in mid-November 2020. The prevalence of E484K ( $n_{E484K}/(n_{\text{screened}} + n_{E484K})$ )  
287 subsequently increased over time, from 4.8% in early December 2020 up to 24.3% in early March  
288 2021. Throughout the study period, we identified fewer N501Y- than E484K-harboring isolates,  
289 with a maximum of 5.9% of N501Y during mid-February 2021. (b) Distribution of different viral  
290 lineages identified by whole genome sequencing. Within our collection (n=282), the majority of  
291 sequenced E484K and S477N fell within the B.1.526 lineage, and N501Y isolates were primarily  
292 but not exclusively within B.1.1.7. Other strains commonly identified in our hospital center include  
293 B.1.1.304, B.1.2, and a lineage L452R-harboring isolates within B.1. (c) Phylogenetic tree of  
294 SARS-CoV-2 variants identified by sequencing and alignment of key spike mutations. Unique  
295 patterns of spike protein mutations present in genomes sequenced from our hospital center with at  
296 least one mutation of interest or concern (E484K, N501Y, S477N, or L452R; n=64) are shown.  
297 Residues at which at least one sample harbored a mutation are displayed above the S-protein  
298 schematic.  
299  
300




301  
302 **Figure 2. Spike protein amino acid substitutions and structural changes represented in**  
303 **sequenced isolates.** Three amino acid changes are characteristic of the B.1.526 lineage: L5F, T95I,  
304 D253G with sub-lineages possessing additional changes S477N, E484K, A701V and Q957R. **(a)**  
305 Maximum-likelihood phylogenetic tree of 2309 SARS-CoV-2 viruses colored according to spike  
306 protein haplotype. Spike protein mutations are labeled on the tree showing the stepwise  
307 accumulation of signature B.1.526 mutations and branching of the B.1.526-E484K and B.1.526-  
308 S477N sub-lineages. An interactive version of this figure is available at  
309 <https://nextstrain.org/groups/blab/ncov/ny/B.1.526>. **(b)** Key mutations of B.1.526 displayed on the  
310 spike trimer. The D253G mutation resides in the antigenic supersite within the N-terminal domain  
311 (NTD), a target for neutralizing antibodies, E484K and S477N at the receptor binding domain  
312 (RBD) interface with the cellular receptor ACE2, and A701V near the furin cleavage site.



314 **Figure 3. Neutralization studies of NYΔ5 and other variant pseudoviruses.** (a) Neutralizing  
315 activities of 12 monoclonal antibodies against pseudoviruses containing S477N or E484K alone  
316 and all five signature B.1.526 mutations (L5F, T95I, D253G, A701V, and E484K or S477N),  
317 termed NYΔ5(E484K) or NYΔ5(S477N). (b) Neutralizing activities of convalescent plasma  
318 (n=20) and vaccinee sera (n=22) against the NYΔ5(E484K) pseudovirus compared to wildtype  
319 pseudovirus. (c) Fold change in convalescent plasma and vaccinee sera neutralization ID<sub>50</sub> of  
320 different variant pseudoviruses compared to wildtype pseudovirus. The data on B.1.1.7, B.1.351  
321 and P.1 were derived from our prior publications<sup>4,23</sup>. Box and whisker plots show each  
322 measurement (symbol), along with median (center line), interquartile range (upper and lower  
323 bounds of each box), and the 9<sup>th</sup> and 91<sup>st</sup> percentile (whiskers) values.  
324





325  
326 **Figure 4. Emergence and spread of SARS-CoV-2 B.1.526 throughout the continental United**  
327 **States. (a)** Changing frequencies of B.1.526 versus B.1.1.7 in samples collected at Columbia  
328 University Irving Medical Center. Over the past four months, cases of B.1.526 have doubled more  
329 rapidly than B.1.1.7 in our hospital catchment area (every 15 days; 95% CI 3 – 22 days) and  
330 continue to rise at a steady rate. Dots show sliding 7-day average variant frequency and lines show  
331 logistic growth fit. **(b)** Changing frequencies of B.1.526 versus B.1.1.7 reported from New York  
332 State. Publicly available data from GISAID also shows consistent logistic growth of both B.1.526  
333 and B.1.1.7 in sequences collected from New York State with growth rate of B.1.526 estimated at  
334 0.032 per day (95% CI 0.029–0.036) and growth rate of B.1.1.7 estimated at 0.040 per day (95%  
335 CI 0.037–0.043). Dots show sliding 7-day average variant frequency and lines show logistic  
336 growth fit. **(c)** Increasing prevalence of B.1.526 in New York City. B.1.526 was initially

337 concentrated in Upper Manhattan but has since spread throughout the city and beyond the  
338 immediate catchment area for our hospital center. **(d)** Spread of B.1.526 throughout the US. Early  
339 B.1.526 genomes from GISAID and from this study (n=61) were concentrated almost exclusively  
340 in New York. Genomes up to January 31, 2021 (n=396) show the beginning of B.1.526's spread  
341 across the United States. As of March 5, 2021, 32 states have at least one confirmed case of B.1.526  
342 (n=2,168), although the lineage is still most densely concentrated in New York. (Map inserts)  
343 Within New York, the spread of B.1.526 is evident from New York City to several counties in the  
344 Southeastern region of the state.

345 **Methods**

346 **Clinical cohort.** This observational study took place at an academic quaternary care center in New  
347 York City. Nasopharyngeal swabs obtained as part of routine clinical care were tested by the  
348 Clinical Microbiology laboratory, and positive specimens were transferred to the Columbia  
349 University Biobank for inactivation and storage.

350 Electronic health records data extracted for this analysis included demographics, laboratory  
351 results, admission, discharge, and transfer dates, current and historical international classification  
352 of disease (ICD 9 and 10) codes extracted from the clinical data warehouse. This study was  
353 reviewed and approved by the Columbia University Institutional Review Board (protocol number  
354 AAAT0123).

355  
356 **PCR screening.** Extended Data Figure 1 describes our overall protocol for variant screening. To  
357 enable rapid PCR-based screening, we prepared RNA using the heat inactivation method in place  
358 of RNA isolation methods<sup>24</sup>. First, 50 µl of nasal swab sample in VTM solution was transferred  
359 into 96-well PCR plates, covered with an adhesive aluminum foil (VWR 60941-076) and  
360 incubated at 95°C for 5 min using the PCR instrument. After the centrifugation of the plate at  
361 >2,100 x g for 5 min, 5 µl of the supernatant from each sample, which contains viral RNA, was  
362 used for the SNP assay.

363 The SNP assay consists of four steps as follows: reverse transcription (RT) of viral RNA,  
364 pre-read of the SNP assay, real-time PCR and post-read of the SNP assay. 5 µl of RNA from the  
365 supernatant was added to 15 µl of the single step RT-qPCR reaction mix, which consists of 5 µl  
366 of TaqPath 1-step RT-qPCR Master Mix, CG (4x) (ThermoFisher Scientific), 500 nM of forward  
367 and reverse primers, 120 nM of VIC-MGB probe, 50 nM of FAM-MGB probe, 1/2000 volume of  
368 ROX Reference Dye (Invitrogen) as the final concentration, and nuclease-free water to adjust the  
369 total reaction volume of 20 µl. Each reaction plate included 8 control wells, 5x10<sup>6</sup> and 5x10<sup>3</sup> copies  
370 of WA-1 (wild type), UK variant and South African variant, which were generated by PCR to  
371 match the variant sequences, and 2 wells with water as no template controls (NTC).

372 The primer pairs and probes used are as follows. For the SNP assay for position **501**, a  
373 primer pair of 501.F: 5'- GGT TTT AAT TGT TAC TTT CCT TTA CA-3' and 501.R: 5'-AGT  
374 TCA AAA GAA AGT ACT ACT ACT CTG TAT G-3' were used with two TaqMan probes  
375 (ThermoFisher Scientific), one for wild type, VIC.N501MGB: [VIC]-AA CCC ACT AAT

376 GGT-MGBNFQ and the other for variant type, FAM.Y501MGB: [FAM]-AAC CCA CTT ATG  
377 GT-MGBNFQ. For position **484**, a primer pair of 484.F: 5'-AGA GAG ATA TTT CAA CTG  
378 AAA TCT ATCAGG-3' and 484.R: 5'-GAA ACC ATA TGA TTG TAA AGG AAA GTA AC-  
379 3' were used with two probes, one for wild type, VIC.E484MGB: [VIC]-ATG GTG TTG AAG  
380 GT-MGBNFQ and the other for variant type, FAM.K484MGB: [FAM]-ATG GTG TTA AAG  
381 GT-MGBNFQ. For position **477**, the primer pair of 477.F and 477.R was used with two probes,  
382 one for wild type, VIC.S477MGB: [VIC]-TTA CAA GGT GTG CTA CCG-MGBNFQ and the  
383 other for variant type, FAM.N477MGB: [FAM]-TTA CAA GGT GTG TTA CCG-MGBNFQ.

384 The reaction plate was subjected to 1) reverse-transcription reaction (RT) at the condition  
385 at 25°C for 2 min, at 50°C for 15 min and a hold at 4°C; 2) SNP assay (pre-read) at 60°C for 30  
386 sec; 3) real-time PCR at 95°C for 20 sec followed by 50 cycles of two-step PCR, at 95°C for 3 sec  
387 and at 60°C for 30 sec with the fast 7500 mode; followed by 4) SNP assay (post-read) at 60°C for  
388 30 sec using ABI 7500 Fast Dx Real-Time PCR Instrument with SDS Software (ThermoFisher  
389 Scientific). The genotype at each key position for each sample was determined by reading the  
390 component signal of the amplification and the allelic discrimination analysis software in the  
391 program.

392  
393 **Whole genome sequencing.** Isolates with cycle threshold (Ct) values below 35 were selected for  
394 sequencing using the ARTIC v3 low-cost protocol<sup>25</sup>. Briefly, RNA was extracted using the Qiagen  
395 RNeasy Mini kit or Zymo DNA/RNA Mini kit. Reverse transcription was performed using  
396 LunaScript RT SuperMix (NEB). Tiling PCR was performed on the cDNA, and amplicons were  
397 barcoded using the Oxford Nanopore Native Barcoding Expansion 96 kit. Pooled barcoded  
398 libraries were then sequenced on an Oxford Nanopore MinION sequencer using R9.4.1 flow cells.  
399 Basecalling was performed in the MinKNOW software v21.02.1. Sequencing runs were monitored  
400 in real-time using RAMPART (<https://artic-network.github.io/rampart/>) to ensure sufficient  
401 genomic coverage with minimal runtime. Consensus sequence generation was performed using  
402 the ARTIC bioinformatics pipeline (<https://github.com/artic-network/artic-ncov2019>). Genomes  
403 were manually curated by visually inspecting sequencing alignment files for verification of key  
404 residues in Geneious v10.2.6.

405

406 **Phylogenetic analysis.** For phylogenetic analysis of isolates sequenced at our hospital center (Fig.  
407 1B-C), genomes were aligned using MAFFT v1.4.0 against the Wuhan-Hu-1 reference sequence  
408 (NC\_045512.1). The resultant alignment was masked to avoid erroneous inclusion of SNPs due to  
409 sequencing errors as proposed by De Maio et al.<sup>26</sup>. To place our isolates in context with publicly  
410 available global sequencing data (Extended Data Fig. 2), we downloaded the Nextstrain North  
411 America dataset from GISAID which includes 4,029 genomes from 334 lineages, and all GISAID  
412 B.1.526 genomes collected between November 2020 and March 2021 (n=2,106). Public genomes  
413 were quality-filtered for <5% ambiguous bases and aligned with CUIMC genomes against the  
414 Wuhan-Hu-1 genome using MAFFT; duplicate sequences were removed, and the alignment was  
415 masked as above (see Supplementary Table 2 for acknowledgments of public genomic data utilized  
416 in this study). IQ-TREE v2.0.3 was used to generate phylogenetic reconstructions with 1,000  
417 ultrafast bootstrap replicates. Interactive Tree of Life (iTOL) was used to visualize all phylogenetic  
418 tree figures.

419 Phylogenetic reconstruction of amino acid changes (Fig. 2A) was conducted using the  
420 Nextstrain<sup>27</sup> workflow at <https://github.com/nextstrain/ncov> which aligns sequences against the  
421 Wuhan-Hu-1 reference via nextalign (<https://github.com/nextstrain/nextclade>), constructs a  
422 maximum-likelihood phylogenetic tree via IQ-TREE<sup>28</sup>, estimates molecular clock branch lengths  
423 via TreeTime<sup>29</sup> and reconstructs nucleotide and amino acid changes also via TreeTime. This  
424 workflow was applied to 2309 SARS-CoV-2 genomes possessing the 9bp deletion  $\Delta$ 106-108 in  
425 ORF1a-nsp6 along with mutation A20262G which demarcates the parent clade to lineage B.1.526  
426 alongside 688 global reference viruses. This analysis was conducted on data downloaded from  
427 [gisaid.org](https://gisaid.org)<sup>30</sup> on April 5, 2021.

428  
429 **Neutralization studies.** We assayed the neutralizing activity of monoclonal antibodies (mAbs),  
430 convalescent plasma, and vaccinee sera against E484K, S477N, and WT (D614G) pseudoviruses,  
431 as well as pseudovirus NY $\Delta$ 5 containing all five signature mutations of B.1.526-E484K (L5F,  
432 T95I, D253G, E484K, D614G, A701V), as previously described<sup>18</sup>. We examined four mAbs with  
433 emergency use authorization (CB6, REGN10987, REGN10933 and LY-CoV555), plus eight  
434 additional RBD mAbs, including ones from our own collection (2-15, 2-7, 1-57, & 2-36)<sup>18</sup> as well  
435 as S309<sup>31</sup>, COV2-2196 & COV2-2130<sup>32</sup>, and C121<sup>33</sup>. We also examined convalescent plasma  
436 collected in Spring of 2020 (n=20 patients), and Moderna and Pfizer vaccinee sera (n=22)<sup>4</sup>. Briefly,

437 Vero E6 cells (ATCC) were seeded in 96-well plates ( $2 \times 10^4$  cells per well). Pseudoviruses were  
438 incubated with serial dilutions of the test samples in triplicate for 30 min at 37 °C. The mixture  
439 was added to cultured cells and incubated for an additional 24 h. Luminescence was measured  
440 using a Britelite plus Reporter Gene Assay System (PerkinElmer), and IC<sub>50</sub> was defined as the  
441 dilution at which the relative light units were reduced by 50% compared with the virus control  
442 wells (virus + cells) after subtraction of the background in the control groups with cells only. The  
443 IC<sub>50</sub> values were calculated using nonlinear regression in GraphPad Prism 8.0. Statistical analysis  
444 was performed using a Wilcoxon matched-pairs signed rank test. Two-tailed p-values are reported.  
445

446 **Growth dynamics.** Growth rates of lineages B.1.1.7 and B.1.526 were estimated in Figure 4a using  
447 7-day sliding window averages of the prevalence of B.1.1.7 and B.1.526, calculated as the number  
448 of sequence-verified samples from each strain divided by the total number of positive samples  
449 with cycle threshold (Ct) values below 35, as this threshold value was used for sequencing. For  
450 Figure 4b, prevalence data was obtained through by downloading “metadata” on April 5, 2021 for  
451 all 15,501 viruses from New York State collected after January 1, 2021. This metadata has PANGO  
452 lineages<sup>34</sup> already assigned to each genome sequence. We calculated a 7-day sliding window of  
453 the frequency of B.1.1.7 and B.1.526 viruses in this dataset going from January 15 to March 21,  
454 2021. This gives a timeseries of daily frequency estimates that we used to infer logistic growth  
455 rate by doing a logit transform on frequency followed by linear regression. The slope of a linear  
456 regression in logit space is equivalent to the growth rate of a logistic growth model following

457 
$$x(t) = \frac{1}{1 + \left(\frac{1}{x_0} - 1\right)e^{-rt}}$$

458 where  $x_0$  is the initial frequency and  $r$  is the logistic growth rate.

459  
460 **Data availability.** All genomes and associated metadata generated as a part of this study have been  
461 uploaded to GISAID at the time of submission; accession numbers will be provided immediately  
462 once available and before final publication. Biological materials (i.e. variant pseudoviruses)  
463 generated as a part of this study will be made available but may require execution of a materials  
464 transfer agreement.

465

466 **Code availability.** Data processing and visualization was performed using publicly available  
467 software and packages, primarily RStudio v1.2.5033, GraphPad Prism v8.4, and iTOL  
468 (<https://itol.embl.de/>). The exact workflow used for phylogenetic analysis of public GISAID data  
469 (Fig. 2a) is available at <https://github.com/blab/ncov-ny>.

470

## 471 **Methods References**

- 472 24 Smyrlaki, I. et al. Massive and rapid COVID-19 testing is feasible by extraction-free  
473 SARS-CoV-2 RT-PCR. *Nat Commun* 11, 4812, doi:10.1038/s41467-020-18611-5 (2020).
- 474 25 Quick, J. *Artic Protocol*, <[https://www.protocols.io/view/ncov-2019-sequencing-protocol-  
475 v3-locost-bh42j8ye](https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye)> (2021).
- 476 26 Demaio, N. Masking strategies for SARS-CoV-2, <[https://virological.org/t/masking-  
477 strategies-for-sars-cov-2-alignments/480](https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480)> (2020).
- 478 27 Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34,  
479 4121-4123, doi:10.1093/bioinformatics/bty407 (2018).
- 480 28 Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic  
481 Inference in the Genomic Era. *Mol Biol Evol* 37, 1530-1534, doi:10.1093/molbev/msaa015  
482 (2020).
- 483 29 Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic  
484 analysis. *Virus Evol* 4, vex042, doi:10.1093/ve/vex042 (2018).
- 485 30 Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from  
486 vision to reality. *Euro Surveill* 22, doi:10.2807/1560-7917.ES.2017.22.13.30494 (2017).
- 487 31 Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV  
488 antibody. *Nature* 583, 290-295, doi:10.1038/s41586-020-2349-y (2020).
- 489 32 Zost, S. J. et al. Rapid isolation and profiling of a diverse panel of human monoclonal  
490 antibodies targeting the SARS-CoV-2 spike protein. *Nat Med* 26, 1422-1427,  
491 doi:10.1038/s41591-020-0998-x (2020).
- 492 33 Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent  
493 individuals. *Nature* 584, 437-442, doi:10.1038/s41586-020-2456-9 (2020).
- 494 34 Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist  
495 genomic epidemiology. *Nat Microbiol* 5, 1403-1407, doi:10.1038/s41564-020-0770-5  
496 (2020).

497 **Acknowledgements:** Biospecimens utilized for this research were obtained from the Columbia  
498 University Biobank (CUB) with technical support from Viplan J. Mahadeva, Sebastian  
499 Fernando and Sylvia T. Parker-Jones. CUB is supported by the Irving Institute for Clinical and  
500 Translational Research (NCATS UL1TR001873). In particular, we thank Muredach Reilly, Eldad  
501 Hod, and the CUB COVID-19 Genomics Consortium (CCGC) for facilitating this effort. We are  
502 also grateful to Lihong Liu and Sho Iketani for technical support. We gratefully acknowledge all  
503 the authors, the originating laboratories responsible for obtaining the specimens, and the  
504 submitting laboratories for generating the genetic sequence and metadata and sharing via the  
505 GISAID Initiative, on which part of the presented research is based (see Supplementary Table 1).  
506 This work was in part funded by NIH/NIDA grant U01 DA053949 (A.-C.U, M.K.A.) and by  
507 support from Andrew & Peggy Cherng, Samuel Yin, Barbara Picower and the JBP Foundation,  
508 Bria Biosciences, Roger & David Wu, and the Bill and Melinda Gates Foundation. Funders and  
509 funding agencies had no role in study design, data collection and analysis, decision to publish, or  
510 preparation of the manuscript.

511  
512 **Competing Interests:** P.W. and D.D.H. are inventors on a provisional patent application on  
513 monoclonal antibodies against SARS-CoV-2. D.D.H. is a member of the scientific advisory board  
514 of Bria Biosciences, which has provided a grant to Columbia University to support this and other  
515 studies on SARS-CoV-2. A.-C.U. has received funding from Merck & Co. unrelated to this study.

516  
517 **Author Contributions: Conceptualization** – A.-C.U., D.D.H., M.K.A., H.M.; **Data curation** –  
518 M.K.A., H.M., J.E.Z., P.W., Z.S., T.B., A.G.-S., A.-C.U.; **Formal analysis** – M.K.A., P.W., J.E.Z.,  
519 T.B., A.G.-S.; **Funding acquisition** – A.-C.U., D.D.H., M.K.A.; **Investigation** – M.K.A., H.M.,  
520 J.E.Z., P.W., T.B.; **Methodology** – M.K.A., H.M., P.W., T.B.; **Supervision** – A.-C.U., D.D.H.;  
521 **Visualization** – M.K.A., P.W., T.B.; **Writing – original draft** – A.-C.U., M.K.A., H.M., D.D.H.;  
522 **Writing – review and editing** – all authors

523  
524 Supplementary Information is available for this paper.

525  
526 Correspondence and requests for materials should be addressed to Anne-Catrin Uhlemann  
527 ([au2110@cumc.columbia.edu](mailto:au2110@cumc.columbia.edu)) or David D. Ho ([dh2994@cumc.columbia.edu](mailto:dh2994@cumc.columbia.edu)).



528 **Extended Data**

**Extended Data Table 1. Clinical characteristics of patients infected with SARS-CoV-2 with and without E484K**

<b>Clinical Characteristic</b>	<b>E484K (n=163)</b>	<b>Wildtype<sup>1</sup> (n=971)</b>	<b>P<sup>2</sup></b>
<b>Demographics</b>			
Male sex, n (%)	80 (49.1)	453 (46.7)	0.62
Age, years (median [IQR])	58 [39, 69]	56 [34, 71]	0.68 <sup>3</sup>
Race and ethnicity, n (%)			0.71
Hispanic/Latino	81 (49.7)	445 (45.8)	
Black	13 (8.0)	101 (10.4)	
White	22 (13.5)	131 (13.5)	
Other	47 (28.8)	294 (30.3)	
Place of residence, n (%)			0.03
NYC	141 (86.5)	788 (81.2)	
Yonkers	8 (4.9)	28 (2.9)	
Outside NYC and Yonkers	14 (8.6)	155 (16.0)	
<b>Comorbidities</b>			
BMI, kg/m <sup>2</sup> (median [IQR])	28.6 [24.9, 33.5]	27.4 [24.0, 31.3]	0.11 <sup>3</sup>
Hypertension, n (%)	61 (39.1)	347 (40.1)	0.89
Diabetes mellitus, n (%)	48 (30.8)	204 (23.6)	0.07
Chronic kidney disease, n (%)	16 (10.3)	87 (10.0)	1.00
Coronary artery disease, n (%)	12 (7.7)	76 (8.8)	0.77
Solid organ transplant, n (%)	5 (3.2)	32 (3.7)	0.95
<b>Cycle threshold value<sup>4</sup> (mean (SD))</b>	30.4 (6.0)	31.8 (6.2)	0.01
<b>Severity of care and outcomes</b>			
Highest level of care (n, %)			0.24
Admitted	53 (32.5)	350 (36.2)	
ED	59 (36.2)	274 (28.3)	
ICU	12 (7.4)	81 (8.4)	
Outpatient	39 (23.9)	263 (27.2)	
Still hospitalized, n (%)	11 (6.7)	27 (2.8)	0.02
Maximum oxygen requirement, n (%)			0.43
Room air	6 (14.6)	75 (23.6)	
Nasal cannula	24 (58.5)	150 (47.2)	
Non-rebreather	6 (14.6)	38 (11.9)	
Non-invasive ventilation <sup>5</sup>	3 (7.3)	20 (6.3)	
Invasive ventilation (intubation)	2 (4.9)	35 (11.0)	
Outcome (%)			0.24
Deceased or discharge to hospice	5 (3.3)	63 (6.7)	
Discharged to home	139 (91.4)	808 (85.5)	
Further care at external facility	8 (5.3)	73 (7.7)	


<sup>1</sup> Wildtype isolates are defined as those without E484K, S477N, N501Y, or L452R mutations

<sup>2</sup> T-tests were performed for continuous variables and chi-squared tests for categorical variables, unless otherwise indicated as below


<sup>3</sup> Due to non-normal distribution, Kruskal-Wallis non-parametric test was used

<sup>4</sup> Cycle threshold value as determined through our rapid qPCR-based screening assay on heat-inactivated nasopharyngeal swab samples

<sup>5</sup> Including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BIPAP), and high flow nasal cannula (HFNC)



**Extended Data Figure 1. Rapid PCR-based screening assay protocol to identify samples harboring key substitutions.** (a) Viral RNA is prepared by heat inactivation and centrifugation. The supernatant is then used for the SNP assay, which entails four steps: the reverse transcription (RT) reaction, pre-PCR reading of the plate to assess background fluorescence (SNP pre-read), real-time PCR, and post-PCR reading of the plate to measure fluorescence (SNP post-read). The runtime for this entire protocol is approximately two hours. (b) Genotype at targeted sites in COVID-19 viral RNA can be determined with two MGB probes, one for wild type (conjugated with VIC) and the other for variant type (conjugated with FAM). (c) Example signals for the variant type (K484; blue), the wild type (E484; red) and samples with no signal (black) are shown.



**Extended Data Figure 2. Phylogenetic reconstruction of the emergence of B.1.526.** To place our B.1.526-E484K isolates within the context of globally circulating SARS-CoV-2 strains, we used the NextStrain North America dataset which includes genomes from 334 lineages, and all GISAID B.1.526 genomes collected between November 2020 and March 2021 (n=2,613 public genomes and 134 CUIMC genomes after quality-filtering and de-duplication). Isolates from this study assigned using Pangolin to B.1.1.7 (blue), B.1.351 (green), and P.2 (teal) fell within these branches, respectively. The majority of our isolates containing E484K fell within B.1.526 (dark pink).